Corporate ActionMay 15, 2026, 04:07 PM
Artelo Biosciences Terminates $6.5M ATM Offering Agreement
AI Summary
Artelo Biosciences, Inc. announced the termination of its At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc., effective May 18, 2026. The agreement, established on July 18, 2025, allowed the company to offer and sell up to $6.5 million in common stock. Prior to termination, Artelo Biosciences had sold 50,858 shares, generating gross proceeds of $451,526.95.
Key Highlights
- Artelo Biosciences terminated its At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc.
- The termination notice was provided on May 11, 2026, effective May 18, 2026.
- The agreement allowed the company to sell up to $6,500,000 in common stock.
- Through May 11, 2026, the company sold 50,858 shares of common stock.
- Gross proceeds from the sales totaled $451,526.95.
Price Impact
More from ARTL